Research Study

A Phase II, Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicentre, Three Month Duration Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
Principal Investigator 
Lynn Straatman

Overview

Body Locations and Systems 
ClinicalTrials.gov# 
NCT03532009
Status 
Recruiting
Study Start/End 
Sep 24, 2019 to Oct 12, 2019
Locations 
Diamond Health Care Centre
Name/Title 
Jackie Chow, Research Manager
Phone 
604-875-5324
Email Address 
jackie.chow@vch.ca
Purpose of Study 

This is an international, multicentre, parallel-group, randomised, double-blind, placebo controlled, phase II study to evaluate the benefits and risks of using sodium zirconium cyclosilicate (ZS) to initiate and intensify renin angiotensin aldosterone system inhibitor (RAASi) therapy in heart failure patients.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.